Life Technologies Corporation announced the launch of Pervenio Lung RS, a risk stratification molecular test to identify early stage lung cancer patients who are at high risk for mortality following surgery.
Disease recurs in a large percentage of early stage, low-risk patients usually at distant sites. This indicates that the patient harbored metastases that were not detected at the time of surgery. Pervenio Lung RS consists of a quantitative PCR (polymerase chain reaction) assay measuring expression of a proprietary 14-gene panel using formalin-fixed, paraffin-embedded tumor specimens. The prognostic genes are related to known molecular pathways, such as KRAS, BRAF, EGFR, HER2, ALK, and p53.
A study published in The Lancet showed the test’s clinical validity as a better predictor of mortality than other known risk factors such as sex, smoking history and cell morphology. In addition, results from two independent, blinded retrospective studies studying 1,500 patients also proved the test’s validity.
For more information call (888) 734-8588 or visit www.lifetechnologies.com.
This article originally appeared on MPR